RFM Stock Overview
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Sensorion SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.73 |
| 52 Week High | €0.80 |
| 52 Week Low | €0.66 |
| Beta | 1.32 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -66.82% |
| 5 Year Change | -40.53% |
| Change since IPO | -71.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| RFM | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -2.5% |
| 1Y | n/a | -19.4% | -0.4% |
Return vs Industry: Insufficient data to determine how RFM performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how RFM performed against the German Market.
Price Volatility
| RFM volatility | |
|---|---|
| RFM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RFM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RFM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 57 | Nawal Ouzren | www.sensorion.com |
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation.
Sensorion SA Fundamentals Summary
| RFM fundamental statistics | |
|---|---|
| Market cap | €196.71m |
| Earnings (TTM) | -€22.06m |
| Revenue (TTM) | €5.57m |
35.3x
P/S Ratio-8.9x
P/E RatioIs RFM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RFM income statement (TTM) | |
|---|---|
| Revenue | €5.57m |
| Cost of Revenue | €0 |
| Gross Profit | €5.57m |
| Other Expenses | €27.63m |
| Earnings | -€22.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.08 |
| Gross Margin | 100.00% |
| Net Profit Margin | -396.45% |
| Debt/Equity Ratio | 6.0% |
How did RFM perform over the long term?
See historical performance and comparison